市場調査レポート
商品コード
1064113

不眠症の世界市場:市場予測、病気の種類別(睡眠の質の低下、睡眠の維持)、投与経路別(オーラルミスト、非経口)、地域別の分析(~2028年)

Insomnia Market Forecasts to 2028 - Global Analysis By Type of Diseases (Poor Quality of Sleep, Sleep Maintenance), Route of Administration (Oral Mists, Parenteral) and By Geography

出版日: | 発行: Stratistics Market Research Consulting | ページ情報: 英文 200+ Pages | 納期: 2~3営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。  詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=152.52円
不眠症の世界市場:市場予測、病気の種類別(睡眠の質の低下、睡眠の維持)、投与経路別(オーラルミスト、非経口)、地域別の分析(~2028年)
出版日: 2022年02月01日
発行: Stratistics Market Research Consulting
ページ情報: 英文 200+ Pages
納期: 2~3営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界の不眠症の市場規模は、2021年は51億2,404万米ドルで、予測期間中に6.2%のCAGRで成長し、2028年には78億744万米ドルに達すると予測されています。

当レポートでは、世界の不眠症市場を調査しており、市場の概要、市場規模や予測、動向、成長要因および阻害要因、治療の種類・病気の種類・投与経路・エンドユーザー・地域別の分析など、包括的な情報を提供しています。

目次

第1章 エグゼクティブサマリー

第2章 序文

第3章 市場動向分析

  • 促進要因
  • 抑制要因
  • 市場機会
  • 脅威
  • アプリケーション分析
  • エンドユーザー分析
  • 新興市場
  • COVID-19の影響

第4章 ポーターのファイブフォース分析

第5章 世界の不眠症市場:治療の種類別

  • 非薬理学的療法
    • 認知行動療法
    • 催眠療法
    • 医療機器
  • 薬理療法
    • 処方睡眠補助剤
    • 市販の睡眠補助剤

第6章 世界の不眠症市場:病気の種類別

  • 睡眠の質の低下
  • 睡眠の維持

第7章 世界の不眠症市場:投与経路別

  • オーラルミスト
  • 非経口

第8章 世界の不眠症市場:製剤別

  • カプセル
  • タブレット

第9章 世界の不眠症市場:医薬品クラス別

  • 抗うつ薬
    • オレキシン拮抗薬
    • メラトニン拮抗薬
  • ベンゾジアゼピン

第10章 世界の不眠症市場:アプリケーション別

  • 女性
  • 男性
  • 高齢者

第11章 世界の不眠症市場:流通チャネル別

  • ドラッグストア
  • 病院薬局
  • オンライン薬局
  • 小売薬局

第12章 世界の不眠症市場:エンドユーザー別

  • ホームケア
  • 医療機器
  • 専門クリニック

第13章 世界の不眠症市場:地域別

  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • ドイツ
    • 英国
    • イタリア
    • フランス
    • スペイン
    • その他欧州
  • アジア太平洋
    • 日本
    • 中国
    • インド
    • オーストラリア
    • ニュージーランド
    • 韓国
    • その他アジア太平洋
  • 南米
    • アルゼンチン
    • ブラジル
    • チリ
    • その他南米
  • 中東・アフリカ
    • サウジアラビア
    • アラブ首長国連邦
    • カタール
    • 南アフリカ
    • その他中東・アフリカ

第14章 主な発展

  • 契約、パートナーシップ、コラボレーション、ジョイントベンチャー
  • 買収と合併
  • 新製品の発売
  • 拡張
  • その他の重要な戦略

第15章 企業プロファイル

  • Astellas
  • Biocodex S A
  • Consumer Healthcare Inc.
  • Dainippon Sumitomo
  • ECR Pharmaceuticals
  • Eisai Co.
  • Flynn Pharma
  • Johnson & Johnson
  • Meda Consumer Healthcare Inc.
  • Merck & Co. Inc.
  • Neurim
  • Pernix Therapeutics
  • Pfizer Inc.
  • Purdue Pharma L.P.
  • Sanofi Pasteur
  • SkyePharma
  • Takeda Pharmaceutical Company
  • Vanda Pharmaceuticals Inc.
  • Zydus Cadila
  • Minerva Neurosciences Inc
図表

List of Tables

  • Table 1 Global Insomnia Market Outlook, By Region (2020-2028) (US $MN)
  • Table 2 Global Insomnia Market Outlook, By Type of Therapy (2020-2028) (US $MN)
  • Table 3 Global Insomnia Market Outlook, By Non Pharmacological Therapy (2020-2028) (US $MN)
  • Table 4 Global Insomnia Market Outlook, By Cognitive Behavioral Therapy (2020-2028) (US $MN)
  • Table 5 Global Insomnia Market Outlook, By Hypnotherapy (2020-2028) (US $MN)
  • Table 6 Global Insomnia Market Outlook, By Medical Devices (2020-2028) (US $MN)
  • Table 7 Global Insomnia Market Outlook, By Pharmacological Therapy (2020-2028) (US $MN)
  • Table 8 Global Insomnia Market Outlook, By Prescription Sleep Aids (2020-2028) (US $MN)
  • Table 9 Global Insomnia Market Outlook, By Over-the-Counter Sleep Aids (2020-2028) (US $MN)
  • Table 10 Global Insomnia Market Outlook, By Type of Diseases (2020-2028) (US $MN)
  • Table 11 Global Insomnia Market Outlook, By Poor Quality of Sleep (2020-2028) (US $MN)
  • Table 12 Global Insomnia Market Outlook, By Sleep Maintenance (2020-2028) (US $MN)
  • Table 13 Global Insomnia Market Outlook, By Route of Administration (2020-2028) (US $MN)
  • Table 14 Global Insomnia Market Outlook, By Oral Mists (2020-2028) (US $MN)
  • Table 15 Global Insomnia Market Outlook, By Parenteral (2020-2028) (US $MN)
  • Table 16 Global Insomnia Market Outlook, By Drug Formulation (2020-2028) (US $MN)

Table17 Global Insomnia Market Outlook, By Capsules (2020-2028) (US $MN)

  • Table 18 Global Insomnia Market Outlook, By Tablet (2020-2028) (US $MN)
  • Table 19 Global Insomnia Market Outlook, By Drug Classes (2020-2028) (US $MN)
  • Table 20 Global Insomnia Market Outlook, By Antidepressants (2020-2028) (US $MN)
  • Table 21 Global Insomnia Market Outlook, By Orexin Antagonist (2020-2028) (US $MN)
  • Table 22 Global Insomnia Market Outlook, By Melatonin Antagonist (2020-2028) (US $MN)
  • Table 23 Global Insomnia Market Outlook, By No benzodiazepines (2020-2028) (US $MN)
  • Table 24 Global Insomnia Market Outlook, By Application (2020-2028) (US $MN)
  • Table 25 Global Insomnia Market Outlook, By Female (2020-2028) (US $MN)
  • Table 26 Global Insomnia Market Outlook, By Male (2020-2028) (US $MN)
  • Table 27 Global Insomnia Market Outlook, By Senior Citizens (2020-2028) (US $MN)
  • Table 28 Global Insomnia Market Outlook, By Distribution Channel (2020-2028) (US $MN)
  • Table 29 Global Insomnia Market Outlook, By Drug Stores (2020-2028) (US $MN)
  • Table 30 Global Insomnia Market Outlook, By Hospital Pharmacies (2020-2028) (US $MN)
  • Table 31 Global Insomnia Market Outlook, By Online Pharmacies (2020-2028) (US $MN)
  • Table 32 Global Insomnia Market Outlook, By Retail Pharmacies (2020-2028) (US $MN)
  • Table 33 Global Insomnia Market Outlook, By End User (2020-2028) (US $MN)
  • Table 34 Global Insomnia Market Outlook, By Homecare (2020-2028) (US $MN)
  • Table 35 Global Insomnia Market Outlook, By Medical Devices (2020-2028) (US $MN)
  • Table 36 Global Insomnia Market Outlook, By Specialty Clinics (2020-2028) (US $MN)

Note- Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.

目次
Product Code: SMRC20396

According to Stratistics MRC, the Global Insomnia Market is accounted for $5124.04 million in 2021 and is expected to reach $7807.44 million by 2028 growing at a CAGR of 6.2% during the forecast period. Insomnia is a common sleep disorder characterized by difficulties in sleep. Insomnia can exist as alone or conjugated with other psychiatric problems. The exact reason for the cause of insomnia is still unknown. It is most common in women and the severity may increase in conditions like postpartum, menopause and pregnancy. Insomnia disorder can be diagnosed in sleep laboratories using various diagnostic devices.

Market Dynamics:

Driver:

Increasing Stress in Work Place

The work conditions are presently a lot of stress for the employees which is further resulting in tension, constant thinking, and loss of sleep. Also, the market is witnessing a huge demand for OTC drugs amongst the different age groups of patients that are suffering from insomnia. Also, owing to the rising incidence of insomnia amongst people due to numerous reasons like tension and stress is likely to act as major drivers for the global growth of the market.

Restraint:

Lack of Clinical Training

Lack of in-depth clinical training in current medical curricula has resulted in delayed or misdiagnosed and improper treatment plans for patients. An increased understanding and screening of insomnia disorder by health care professionals could result in broader public knowledge of insomnia disorder and sleep health.

Opportunity:

Development of New Technologies

The development of new technologies and the introduction of medical devices are anticipated to boost the market growth. The major market players are playing a significant role in the market. For instance, Eisai Co. Ltd received approval from the US Food and Drug Administration (FDA) and the firm launched its in-house discovered orexin receptor antagonist DAYVIGO (lemborexant) CIV for the treatment of adults with insomnia, characterized by difficulties with sleep onset and/or sleep maintenance in the United States.

Threat:

Strict Condition

As insomnia's drugs can be prescribed by doctors only in special cases and under strict conditions, like morphine. These prescriptions are strictly determined by distribution and storage licenses and laws which act ac a major threat for the growth of the market.

Benzodiazepines segment is expected to be the largest during the forecast period

Benzodiazepines are a type of sedative medication. This means they slow down the body and brain's functions. They can be used to help with anxiety and insomnia (difficult getting to sleep or staying asleep) Benzodiazepines are a group of CNS depressants which induce feelings of calm (anxiolysis), drowsiness and sleep. They act by facilitating the binding of the inhibitory neurotransmitter GABA at various GABA receptors throughout the CNS.

The over-the-counter segment is expected to have the highest CAGR during the forecast period

The over-the-counter sleep aids segment is going to have lucrative growth during the forecast period attributing to the growth of this market includes easier availability, low prices, and publicity regarding the side effects of the prescription sleep aids has also steered the patients towards over-the-counter sleep aid.

Region with highest share:

The North America is projected to hold the highest market share, owing to the growing need for sleep disorder treatment in the US and Canada coupled with the growing prevalence of sleep disorders is driving the market. According to the American Academy of Sleep Medicine 2020, stress can result in adjustment insomnia, which may affect up to 20% of people in the United States each year. Poor sleeping habits in children lead to behavioural insomnia of childhood, affecting 30% of children. Prescription drugs, substance abuse, medical disorders, and mental health conditions cause insomnia, with about 3% of the population having this type of sleep issue. Specific causes include depression, drug withdrawal, obesity, and anaemia.

Region with highest CAGR:

Asia Pacific is projected to have the highest CAGR. The market expansion in this province can be highly attributed to increased stress level of working population along with shift-work related sleep disorders. Asia-Pacific excluding Japan (APEJ) will also remain a remunerative region for growth of the market Governments in the province are constantly focusing on improving their healthcare system along with the provision of favourable reimbursement policies, which in turn might impact the insomnia market.

Key players in the market:

Some of the key players profiled in the Insomnia Market include Astellas, Biocodex S A, Consumer Healthcare Inc., Dainippon Sumitomo, ECR Pharmaceuticals, Eisai Co., Flynn Pharma, Johnson & Johnson, Meda Consumer Healthcare Inc., Merck & Co. Inc., Neurim, Pernix Therapeutics, Pfizer Inc., Purdue Pharma L.P., Sanofi Pasteur, SkyePharma, Takeda Pharmaceutical Company, Vanda Pharmaceuticals Inc. Zydus Cadila, Minerva Neurosciences Inc.

Key developments:

In in June 2020: Eisai Co. Ltd launched in-house discovered orexin receptor antagonist DAYVIGO (lemborexant) CIV for the treatment of adults with insomnia, characterized by difficulties with sleep onset and/or sleep maintenance. All these factors are projected to increase the growth of the insomnia treatment market in the North Amer.

In July 2019: Zydus Cadila launched Ramelteon tablets, used to treat insomnia, in the US market.

In January 2021: Minerva Neurosciences Inc. and Royalty Pharma plc entered into an agreement under which Royalty Pharma will acquire Minerva's royalty interest in seltorexant. Seltorexant, a selective orexin 2 receptor antagonist, is currently in Phase 3 development for the treatment of major depressive disorder (MDD) with insomnia symptoms.

Type of Therapy's Covered:

  • Non Pharmacological Therapy
  • Pharmacological Therapy

Type of Disease's Covered:

  • Poor Quality of Sleep
  • Sleep Maintenance

Route of Administrations Covered:

  • Oral Mists
  • Parenteral

Drug Formulations Covered:

  • Capsules
  • Tablet

Drug Classes Covered:

  • Antidepressants
  • Benzodiazepines

Applications Covered:

  • Female
  • Male
  • Senior Citizens

Distribution Channels Covered:

  • Drug Stores
  • Hospital Pharmacies
  • Online Pharmacies
  • Retail Pharmacies

End Users Covered:

  • Homecare
  • Medical Devices
  • Specialty Clinics

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2020, 2021, 2022, 2025 and 2028
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Application Analysis
  • 3.7 End User Analysis
  • 3.8 Emerging Markets
  • 3.9 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Insomnia Market, By Type of Therapy

  • 5.1 Introduction
  • 5.2 Non Pharmacological Therapy
    • 5.2.1 Cognitive Behavioral Therapy
    • 5.2.2 Hypnotherapy
    • 5.2.3 Medical Devices
  • 5.3 Pharmacological Therapy
    • 5.3.1 Prescription Sleep Aids
    • 5.3.2 Over-the-Counter Sleep Aids

6 Global Insomnia Market, By Type of Diseases

  • 6.1 Introduction
  • 6.2 Poor Quality of Sleep
  • 6.3 Sleep Maintenance

7 Global Insomnia Market, By Route of Administration

  • 7.1 Introduction
  • 7.2 Oral Mists
  • 7.3 Parenteral

8 Global Insomnia Market, By Drug Formulation

  • 8.1 Introduction
  • 8.2 Capsules
  • 8.3 Tablet

9 Global Insomnia Market, By Drug Classes

  • 9.1 Introduction
  • 9.2 Antidepressants
    • 9.2.1 Orexin Antagonist
    • 9.2.2 Melatonin Antagonist
  • 9.3 Benzodiazepines

10 Global Insomnia Market, By Application

  • 10.1 Introduction
  • 10.2 Female
  • 10.3 Male
  • 10.4 Senior Citizens

11 Global Insomnia Market, By Distribution Channel

  • 11.1 Introduction
  • 11.2 Drug Stores
  • 11.3 Hospital Pharmacies
  • 11.4 Online Pharmacies
  • 11.5 Retail Pharmacies

12 Global Insomnia Market, By End User

  • 12.1 Introduction
  • 12.2 Homecare
  • 12.3 Medical Devices
  • 12.4 Specialty Clinics

13 Global Insomnia Market, By Geography

  • 13.1 Introduction
  • 13.2 North America
    • 13.2.1 US
    • 13.2.2 Canada
    • 13.2.3 Mexico
  • 13.3 Europe
    • 13.3.1 Germany
    • 13.3.2 UK
    • 13.3.3 Italy
    • 13.3.4 France
    • 13.3.5 Spain
    • 13.3.6 Rest of Europe
  • 13.4 Asia Pacific
    • 13.4.1 Japan
    • 13.4.2 China
    • 13.4.3 India
    • 13.4.4 Australia
    • 13.4.5 New Zealand
    • 13.4.6 South Korea
    • 13.4.7 Rest of Asia Pacific
  • 13.5 South America
    • 13.5.1 Argentina
    • 13.5.2 Brazil
    • 13.5.3 Chile
    • 13.5.4 Rest of South America
  • 13.6 Middle East & Africa
    • 13.6.1 Saudi Arabia
    • 13.6.2 UAE
    • 13.6.3 Qatar
    • 13.6.4 South Africa
    • 13.6.5 Rest of Middle East & Africa

14 Key Developments

  • 14.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 14.2 Acquisitions & Mergers
  • 14.3 New Product Launch
  • 14.4 Expansions
  • 14.5 Other Key Strategies

15 Company Profiling

  • 15.1 Astellas
  • 15.2 Biocodex S A
  • 15.3 Consumer Healthcare Inc.
  • 15.4 Dainippon Sumitomo
  • 15.5 ECR Pharmaceuticals
  • 15.6 Eisai Co.
  • 15.7 Flynn Pharma
  • 15.8 Johnson & Johnson
  • 15.9 Meda Consumer Healthcare Inc.
  • 15.10 Merck & Co. Inc.
  • 15.11 Neurim
  • 15.12 Pernix Therapeutics
  • 15.13 Pfizer Inc.
  • 15.14 Purdue Pharma L.P.
  • 15.15 Sanofi Pasteur
  • 15.16 SkyePharma
  • 15.17 Takeda Pharmaceutical Company
  • 15.18 Vanda Pharmaceuticals Inc.
  • 15.19 Zydus Cadila
  • 15.20 Minerva Neurosciences Inc